Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic adipose-derived mesenchymal stem cells (IIS-FJD)
- Development stage
- Unknown
- Lead developer
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic, Subconjunctival
01
Overview
Allogeneic adipose-derived mesenchymal stem cells (ASCs) are a type of multipotent cell therapy being developed by the Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. These cells are harvested from the adipose tissue of healthy donors and are utilized for their potent immunomodulatory, anti-inflammatory, and regenerative properties. In the clinical setting, specifically within the CELOPHIN trial, they are administered via subconjunctival and topical conjunctival injection to treat severe ocular surface diseases characterized by progressive scarring. The primary indications include cicatricial conjunctivitis associated with Stevens-Johnson syndrome, Lyell syndrome (toxic epidermal necrolysis), and mucous membrane pemphigoid. The therapy aims to modulate the local immune response and inhibit the fibrotic processes that lead to vision-threatening conjunctival symblepharon and ocular surface failure.
- Other names
- allogeneic adipose-derived mesenchymal stem cellsallogeneic ASCsallogeneic adipose-derived MSCs
Beyond the preview
Go deeper on allogeneic adipose-derived mesenchymal stem cells (IIS-FJD).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic adipose-derived mesenchymal stem cells (IIS-FJD).